Abstract
Recent studies have illustrated the important role of alloantibodies in mediating renal allograft rejection. Compared to T-cell mediated-rejection, antibody-mediated rejection is usually more refractory to conventional anti-rejection treatment and more likely to contribute to allograft failure. Antibody-mediated rejection can occur in three principal forms: hyperacute, acute, and chronic active. This brief review aims to characterize the main pathological features attributed to antibody-mediated rejection including light microscopy manifestations, ultrastructural alterations, and immunopathologic markers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
